3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
5
Thoracic
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Ovarian Neoplasms
16
Uterine Cervical Neoplasms
8
Melanoma
7
Colorectal Neoplasms
7
Fallopian Tube Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Neoplasm Metastasis
5
Breast Neoplasms
5
Recurrence
4
Triple Negative Breast Neoplasms
3
Pancreatic Neoplasms
3
Head and Neck Neoplasms
3
Carcinoma, Ovarian Epithelial
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Prostatic Neoplasms
2
Neoplasms
2
Lymphoma
2
Endometrial Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Renal Cell
2
Carcinoma, Merkel Cell
2
Carcinoma, Hepatocellular
2
Anus Neoplasms
2
Vulvar Neoplasms
1
Vulvar Diseases
1
Vaginal Neoplasms
1
Uterine Cervical Dysplasia
1
Turcot syndrome
1
Squamous Cell Carcinoma of Head and Neck
1
Interventions
pembrolizumab
24
Paclitaxel
7
Docetaxel
7
Cyclophosphamide
7
Carboplatin
7
fludarabine
6
Taxes
6
Nivolumab
6
Trastuzumab
5
Magnetic Resonance Spectroscopy
5
atezolizumab
4
Specimen Handling
4
Psychiatric Rehabilitation
4
Polymerase Chain Reaction
4
Gemcitabine
4
Fluorouracil
4
Cisplatin
4
tisotumab vedotin
3
fludarabine phosphate
3
Radiation
3
Oxaliplatin
3
Leucovorin
3
Irinotecan
3
Ipilimumab
3
Gene Expression Profiling
3
Drug Therapy
3
Counseling
3
Albumin-Bound Paclitaxel
3
zimberelimab
2
ulixertinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
Interleukin-2
×
Gynecologic
×
Clear all
NCT05086692
2025-07-09
ABILITY-1
Medicenna Therapeutics, Inc.
Phase 1/2
Recruiting
115 enrolled